About SI-BONE, Inc. 
SI-BONE, Inc.
Pharmaceuticals & Biotechnology
SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
Company Coordinates 
Company Details
471 El Camino Real Ste 101 , SANTA CLARA CA : 95050-4482
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 61 Schemes (38.42%)
Foreign Institutions
Held by 86 Foreign Institutions (9.52%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Jeffrey Dunn
Chairman of the Board, President, Chief Executive Officer
Mr. Timothy Davis
Lead Independent Director
Mr. Mark Foley
Independent Director
Dr. John Freund
Independent Director
Ms. Jeryl Hilleman
Independent Director
Mr. Gregory Hinckley
Independent Director
Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
Pharmaceuticals & Biotechnology
USD 696 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.64
-13.95%
4.09






